Fezolinetant Benefits Women Not Suited for Hormone Therapy
PHILADELPHIA — Fezolinetant (Veozah) improved menopause-related vasomotor symptoms in women unsuited or unwilling to take hormone therapy, according to a pooled analysis of two phase III studies. The analysis of the SKYLIGHT-1 and -2 trials showed significant improvements with two different dosages of the newly approved drug versus placebo in both the frequency and severity […]